| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (NCT05113537) | Vadim S Koshkin | 2022-07-08 |
| 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer (NCT05547386) | Mayo Clinic | 2022-05-09 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study (NCT05053152) | NRG Oncology | 2022-04-20 |
| Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT05168618) | University of Utah | 2022-03-29 |
| Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer (NCT05037500) | Roswell Park Cancer Institute | 2022-01-26 |
| Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones (NCT04616547) | National Cancer Institute (NCI) | 2021-12-18 |
| A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (NCT04455750) | Alliance for Clinical Trials in Oncology | 2021-10-14 |
| Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion (NCT04976257) | Ryan Kohlbrenner, MD | 2021-10-13 |
| 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer (NCT04716725) | Thomas Hope | 2021-09-28 |
| 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression (NCT04927663) | Rahul Aggarwal | 2021-08-10 |
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer (NCT04754425) | M.D. Anderson Cancer Center | 2021-07-15 |
| Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy (NCT04915508) | Jonsson Comprehensive Cancer Center | 2021-06-23 |
| 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy (NCT04928820) | Jonsson Comprehensive Cancer Center | 2021-06-16 |
| An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer (NCT04777071) | University of Washington | 2021-05-17 |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (NCT04734730) | City of Hope Medical Center | 2021-05-04 |
| Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer (NCT04489719) | University of Washington | 2021-04-16 |
| Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer (NCT03902951) | Jonsson Comprehensive Cancer Center | 2021-03-17 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial (NCT04693377) | M.D. Anderson Cancer Center | 2021-03-16 |
| ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT04471974) | Rahul Aggarwal | 2021-01-26 |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study (NCT04585932) | M.D. Anderson Cancer Center | 2020-11-24 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (NCT04071236) | National Cancer Institute (NCI) | 2020-10-14 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (NCT04423211) | ECOG-ACRIN Cancer Research Group | 2020-10-08 |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers (NCT04388852) | M.D. Anderson Cancer Center | 2020-08-20 |
| Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer (NCT03649841) | University of Washington | 2020-06-29 |
| Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer (NCT04267887) | OHSU Knight Cancer Institute | 2020-05-11 |
| Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer (NCT03999515) | University of Washington | 2020-04-27 |
| Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer (NCT04279561) | Jonsson Comprehensive Cancer Center | 2020-04-16 |
| Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring (NCT05054296) | M.D. Anderson Cancer Center | 2020-03-23 |
| A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer (NCT04190446) | Mayo Clinic | 2020-01-06 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes (NCT04501913) | City of Hope Medical Center | 2019-12-24 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04033432) | Northwestern University | 2019-09-20 |
| An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer (NCT04134208) | M.D. Anderson Cancer Center | 2019-09-19 |
| PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (NCT03873805) | City of Hope Medical Center | 2019-08-20 |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer (NCT03751436) | Roswell Park Cancer Institute | 2019-08-02 |
| A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (NCT03784677) | M.D. Anderson Cancer Center | 2019-07-29 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer (NCT03581500) | M.D. Anderson Cancer Center | 2019-02-06 |
| Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (NCT03317392) | National Cancer Institute (NCI) | 2019-02-04 |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (NCT03678025) | SWOG Cancer Research Network | 2018-09-24 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer (NCT04050215) | Jonsson Comprehensive Cancer Center | 2018-04-02 |
| Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (NCT03360721) | M.D. Anderson Cancer Center | 2018-03-06 |
| Genetic Testing for Men With Metastatic Prostate Cancer (NCT03503097) | University of Washington | 2017-08-21 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies (NCT03217747) | M.D. Anderson Cancer Center | 2017-08-02 |
| Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03204812) | M.D. Anderson Cancer Center | 2017-07-14 |